Tailoring a novel colorectal cancer stem cell-targeted therapy by inhibiting the SMYD3/c-MYC axis

Cancer stem cells (CSCs) are responsible for colorectal cancer (CRC) chemoresistance, recurrence, and metastasis. Therefore, identifying molecular stemness targets that are involved in tumor growth is crucial for effective treatment. Here, we performed an extensive in vitro and in vivo molecular and functional characterization, revealing the pivotal role of the lysine methyltransferase SET and MYND Domain Containing 3 (SMYD3) in colorectal cancer stem cell (CRC-SC) biology. Specifically, we showed that SMYD3 interacts with and methylates c-MYC at K158 and K163, thereby modulating its transcriptional activity, which is implicated in stemness and colorectal malignancy. Our in vitro data suggest that SMYD3 pharmacological inhibition or its stable genetic ablation affects the clonogenic and self-renewal potential of patient-derived CRC-SCs and organoids by altering their molecular signature. Moreover, we found that SMYD3 stable knock-out or pharmacological inhibition drastically reduces CRC tumorigenicity in vivo and CRC-SC metastatic potential. Overall, our findings identify SMYD3 as a promising therapeutic target acting directly on c-MYC, with potential implications for countering CRC-SC proliferation and metastatic dissemination.

Authors

Institutions

Publication Details

Journal
Signal Transduction and Targeted Therapy
Published
2025-06-30
DOI
https://doi.org/10.1038/s41392-025-02290-z
Citations
7
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
5.64

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tailoring a novel colorectal cancer stem cell-targeted therapy by inhibiting the SMYD3/c-MYC axis

Vito Spilotro, Gianluigi Gigante, Leonardo Vincenti, Greta Varchi et al.
7 citations
Signal Transduction and Targeted Therapy
Epigenetics and DNA Methylation
5.64
article

Tailoring a novel colorectal cancer stem cell-targeted therapy by inhibiting the SMYD3/c-MYC axis

Vito Spilotro, Gianluigi Gigante, Leonardo Vincenti, Greta Varchi, Vittoria Disciglio, Giusy Bianco, Cristiano Simone, Martina Lepore Signorile, Valentina Grossi, Katia De Marco, Marta Lucchetta, Giovanna Forte, Claudia Ferroni, Francesco Albano, Giuliano Lantone, Alberto Del Río, Candida Fasano, Paola Sanese, Valerio Lantone, Elisabetta Di Nicola, Marialaura Latrofa, Marica Ficorilli, Chiara Dossena, Raffaele Armentano, Anna Mestice, Nicoletta Labarile, Erica Torchia, Loris De Cecco
article en
7 citations

Abstract

Cancer stem cells (CSCs) are responsible for colorectal cancer (CRC) chemoresistance, recurrence, and metastasis. Therefore, identifying molecular stemness targets that are involved in tumor growth is crucial for effective treatment. Here, we performed an extensive in vitro and in vivo molecular and functional characterization, revealing the pivotal role of the lysine methyltransferase SET and MYND Domain Containing 3 (SMYD3) in colorectal cancer stem cell (CRC-SC) biology. Specifically, we showed that SMYD3 interacts with and methylates c-MYC at K158 and K163, thereby modulating its transcriptional activity, which is implicated in stemness and colorectal malignancy. Our in vitro data suggest that SMYD3 pharmacological inhibition or its stable genetic ablation affects the clonogenic and self-renewal potential of patient-derived CRC-SCs and organoids by altering their molecular signature. Moreover, we found that SMYD3 stable knock-out or pharmacological inhibition drastically reduces CRC tumorigenicity in vivo and CRC-SC metastatic potential. Overall, our findings identify SMYD3 as a promising therapeutic target acting directly on c-MYC, with potential implications for countering CRC-SC proliferation and metastatic dissemination.

Signal Transduction and Targeted TherapyVol. 10(1)
Institute of Organic Synthesis and Photoreactivity (IT), Ospedale L. Bonomo (IT), Gastroenterology Hospital "Saverio de Bellis" (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Innova (Italy) (IT), University of Bari Aldo Moro (IT)
European Commission, Russian Foundation for Basic Research, Ministero della Salute, Associazione Italiana per la Ricerca sul Cancro
Good health and well-being
Openalex Percentile: Top 4%
Epigenetics and DNA Methylation
5.64
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.